Pop singer Lorde slammed Spotify’s AI ‘About the Song’ feature, claiming it’s full of nothing but false details — and now subscribers are starting to catch on
THE SO WHAT
When artists publicly call out AI-generated metadata as wrong, the product stops being a delight and starts eroding trust in the whole surface. If you’re shipping AI explanations or context, invest in provenance and human review — hallucinated “facts” about creative work are a fast path to user backlash and rights-holder friction.
READ THE SOURCE
MORE FROM THE WIRE
Applied AIKioxia showcases the world’s fastest SSD with mind-blowing 10M IOPS and a staggering 50 DWPD endurance
Storage is quietly catching up to AI accelerators—10M IOPS over PCIe 6.0 with 50 DWPD means fewer bottlenecks moving training/inference data and more aggressive local caching. If you're architecting AI infra, start modeling what happens when storage ceases to be your constraint and network or memory bandwidth becomes the choke point instead.
Applied AIPatients, families, doctors, and nurses are increasingly turning to AI tools, such as Face2Gene, to help identify rare and hard-to-diagnose diseases
Diagnostic authority is getting redistributed from institutions to a patient–clinician–model triad—tools like Face2Gene move ‘zebra hunting’ from specialist art toward pattern-matching infrastructure. Health systems and payers need to decide quickly whether to standardize, reimburse, and govern these tools or let ad hoc, patient-driven adoption set the default.
Applied AIAnthropic CEO says AI backlash is ‘fundamentally a crisis of trust’
When a major lab CEO calls the backlash a “crisis of trust,” reputational risk moves from PR issue to core constraint on deployment and policy wins. Operators building on frontier models should assume higher scrutiny on provenance, safety posture, and external validation—not just raw capability—over the next 6–12 months.
Anthropic CEO Dario Amodei says the way for AI to win over the public is to 'actually' cure cancer
Tying AI legitimacy to outcomes like “actually curing cancer” raises the bar from productivity gains to visible, life-changing wins—anything less will feel like overpromising. If you’re selling AI into regulated or high-stakes domains, anchor your value prop in concrete, near-term outcomes you can prove this year, not hypothetical breakthroughs.